Correspondence 0001193125-23-267298 from Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc.
Date: Oct. 31, 2023 · CIK: 0001907108 · Accession: 0001193125-23-267298
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274777
Letter
VIA EDGAR Division of Corporation Finance Attention: Office of Life Sciences Washington, D.C. Registration Statement on Form S-1 File No. 333-274777
Re: Lexeo Therapeutics, Inc.
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned, for themselves and on behalf of the several underwriters, hereby join in the request of Lexeo Therapeutics, Inc. that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective at 4:00 p.m., Eastern time, on November 2, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 of the General Rules and Regulations under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
The undersigned advises that the several underwriters have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
* * *
[Signature Page Follows]
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP October 31, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Attention: Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-274777 Dear Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned, for themselves and on behalf of the several underwriters, hereby join in the request of Lexeo Therapeutics, Inc. that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective at 4:00 p.m., Eastern time, on November 2, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 of the General Rules and Regulations under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. The undersigned advises that the several underwriters have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable. * * * [Signature Page Follows] Very truly yours, J.P. MORGAN SECURITIES LLC LEERINK PARTNERS LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED RBC CAPITAL MARKETS, LLC as representatives of the several underwriters J.P. MORGAN SECURITIES LLC By: /s/ David Ke Name: David Ke Title: Managing Director LEERINK PARTNERS LLC By: /s/ Stuart Nayman Name: Stuart Nayman Title: Managing Director, Senior Legal Counsel STIFEL, NICOLAUS & COMPANY, INCORPORATED By: /s/ Nicholas Oust Name: Nicholas Oust Title: Managing Director RBC CAPITAL MARKETS, LLC By: /s/ Noël K. Brown Name: Noël K. Brown Title: Managing Director Head of US Biotechnology Investment Banking [Signature Page to Underwriters’ Acceleration Request Letter]